BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
rs7903146
,
PBX1
,
T cell receptor signaling pathway
,
Ischemia
,
Hippocampus
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
Akt
Summary
General Info
Curated Studies
Most Correlated Studies
CD8-positive melanoma-infiltrating lymphocytes treated with AKT inhibitor VIII (AKTi-1-2)
T helper D10 cells time course TCR activation in the presence of Akt inhibition
PDK1 null and Akt inhibitor treated cytotoxic T-lymphocyte expression data
Breast adenocarcinoma MCF7 and colon carcinoma HCT116 cells treated w/ small molecule AKT inhibitor
L1000 CMAP - Breast carcinoma BT20 cells treated with small molecule perturbagens
Explore Curated Studies Results
Literature
Most Relevant Literature
Activity-induced synaptic structural modifications by Akt.
A multi-layered network model identifies Akt1 as a common modulator of neurodegeneration.
Identification of XAF1 as an endogenous AKT inhibitor.
Redundant roles of AKT1 and AKT2 in fertility, estrous cyclicity and endometrial gland development.
Integrated analyses of 5 mC, 5hmC methylation and gene expression reveal pathology-associated AKT3 g…
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Autonomic Phenotype Before and After Akt Inhibition
Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Ca…
Safety, Pharmacokinetics (PK) of AKT and MEK Combination
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ